OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

YY Kong, H Yoshida, I Sarosi, HL Tan, E Timms… - Nature, 1999 - nature.com
YY Kong, H Yoshida, I Sarosi, HL Tan, E Timms, C Capparelli, S Morony…
Nature, 1999nature.com
The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as
TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation
factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a
disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and
completely lack osteoclasts as a result of an inability of osteoblasts to support
osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit …
Abstract
The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.
nature.com